Taiwan FDA registration 0323168158e1a3c02e1a26e3b06576ba

"Leica" Bond Ready-to-Use Primary Antibody S-100 (Polyclonal)(Non-Sterile)

TW: “錸卡”邦德即用型S100一級抗體(多株抗體) (未滅菌)
Taiwan flagTaiwan·Risk Class 1·MD·LEICA BIOSYSTEMS NEWCASTLE LTD.·Registered Dec 03, 2018 – Dec 03, 2028Active
Registration details
Analysis ID
0323168158e1a3c02e1a26e3b06576ba
License Form
Ministry of Health Medical Device Import No. 019872
Customs Code
DHA09401987203
Company information
Manufacturer Country
United Kingdom
Product details
Intended Use
Limited to the first level identification range of immunopathological histochemical reagents and kits (B.1860) of the Measures for the Administration of Medical Devices.
Product Type (Level 1)
B Hematology and pathology devices
Product Type (Level 2)
B1860 Immunopathological histochemical reagents and kits
Import Information
Imported from abroad
Dates and status
Registration Date
Dec 03, 2018
Expiry Date
Dec 03, 2028
About this record

Access comprehensive regulatory information for "Leica" Bond Ready-to-Use Primary Antibody S-100 (Polyclonal)(Non-Sterile) in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 1 medical device is registered under number 0323168158e1a3c02e1a26e3b06576ba and manufactured by LEICA BIOSYSTEMS NEWCASTLE LTD.. The authorized representative in Taiwan is BECKMAN COULTER TAIWAN INC., TAIWAN BRANCH (U.S.A.).

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.

Free DatabasePowered by Pure Global AI89,000+ Devices